<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Inform</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Inform</journal-id>
    <journal-id journal-id-type="publisher-id">CIX</journal-id>
    <journal-id journal-id-type="hwp">spcix</journal-id>
    <journal-title-group>
      <journal-title>Cancer Informatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1176-9351</issn>
    <publisher>
      <publisher-name>SAGE Publications</publisher-name>
      <publisher-loc>Sage UK: London, England</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7672756</article-id>
    <article-id pub-id-type="doi">10.1177/1176935120972377</article-id>
    <article-id pub-id-type="publisher-id">10.1177_1176935120972377</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software or Database Review</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>vcfView: An Extensible Data Visualization and Quality Assurance Platform for Integrated Somatic Variant Analysis</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>O’Sullivan</surname>
          <given-names>Brian</given-names>
        </name>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Seoighe</surname>
          <given-names>Cathal</given-names>
        </name>
        <xref ref-type="corresp" rid="corresp1-1176935120972377"/>
      </contrib>
      <aff id="aff1-1176935120972377">School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, Galway, Ireland</aff>
    </contrib-group>
    <author-notes>
      <corresp id="corresp1-1176935120972377">Cathal Seoighe, School of Mathematics, Statistics and Applied Mathematics, National University of Ireland Galway, University Road, Galway H91TK33, Ireland. Email: <email>Cathal.Seoighe@nuigalway.ie</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>11</day>
      <month>11</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>19</volume>
    <elocation-id>1176935120972377</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>7</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>19</day>
        <month>10</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder>
      <license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <sec id="section1-1176935120972377">
        <title>Motivation:</title>
        <p>Somatic mutations can have critical prognostic and therapeutic implications for cancer patients. Although targeted methods are often used to assay specific cancer driver mutations, high throughput sequencing is frequently applied to discover novel driver mutations and to determine the status of less-frequent driver mutations. The task of recovering somatic mutations from these data is nontrivial as somatic mutations must be distinguished from germline variants, sequencing errors, and other artefacts. Consequently, bioinformatics pipelines for recovery of somatic mutations from high throughput sequencing typically involve a large number of analytical choices in the form of quality filters.</p>
      </sec>
      <sec id="section2-1176935120972377">
        <title>Results:</title>
        <p>We present vcfView, an interactive tool designed to support the evaluation of somatic mutation calls from cancer sequencing data. The tool takes as input a single variant call format (VCF) file and enables researchers to explore the impacts of analytical choices on the mutant allele frequency spectrum, on mutational signatures and on annotated somatic variants in genes of interest. It allows variants that have failed variant caller filters to be re-examined to improve sensitivity or guide the design of future experiments. It is extensible, allowing other algorithms to be incorporated easily.</p>
      </sec>
      <sec id="section3-1176935120972377">
        <title>Availability:</title>
        <p>The shiny application can be downloaded from GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/BrianOSullivanGit/vcfView">https://github.com/BrianOSullivanGit/vcfView</ext-link>). All data processing is performed within <italic>R</italic> to ensure platform independence. The app has been tested on RStudio, version 1.1.456, with base <italic>R</italic> 3.6.2 and Shiny 1.4.0. A vignette based on a publicly available data set is also available on GitHub.</p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>
        <italic>R</italic>
      </kwd>
      <kwd>cancer</kwd>
      <kwd>shiny</kwd>
      <kwd>visualization</kwd>
      <kwd>VCF</kwd>
      <kwd>variant filtering</kwd>
      <kwd>SNV</kwd>
      <kwd>indel</kwd>
      <kwd>SBS</kwd>
      <kwd>COSMIC v3</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>January-December 2020</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>typesetter</meta-name>
        <meta-value>ts1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="section4-1176935120972377">
    <title>Introduction</title>
    <p>A broad array of variant callers and computational pipelines serving a diverse range of research requirements has been developed to identify somatic mutations from DNA sequencing data. Each method comes with its own set of performance characteristics.<sup><xref rid="bibr1-1176935120972377" ref-type="bibr">1</xref></sup> Despite differences in calling algorithms and applications, most use tumour and normal next-generation sequencing (NGS) data, aligned to a reference as input and output detailed tumour-specific single nucleotide variants and indel records in variant call format (VCF).<sup><xref rid="bibr2-1176935120972377" ref-type="bibr">2</xref></sup> One of the most popular callers in clinical oncology,<sup><xref rid="bibr3-1176935120972377" ref-type="bibr">3</xref></sup> Mutect2,<sup><xref rid="bibr4-1176935120972377" ref-type="bibr">4</xref></sup> has been shown to perform well in terms of overall balanced accuracy.<sup><xref rid="bibr1-1176935120972377" ref-type="bibr">1</xref></sup> It employs a series of filters to flag likely false-positive variants, resulting from biases, artefacts, or failure to meet confidence thresholds.</p>
    <p>The frequency spectrum of mutations is often of particular interest. Somatic mutations with relatively high frequency (&gt;0.25, accounting for ploidy and sample purity)<sup><xref rid="bibr5-1176935120972377" ref-type="bibr">5</xref></sup> are often clonal (i.e. they occur in every cancer cell) and some of these may be cancer driver mutations and therefore of particular interest for precision oncology. The somatic mutation spectrum can also provide information about the evolutionary dynamics of the tumour.<sup><xref rid="bibr5-1176935120972377" ref-type="bibr">5</xref>,<xref rid="bibr6-1176935120972377" ref-type="bibr">6</xref></sup> In the case of blood cancers, variant frequencies are used for risk stratification and prognosis for a number of myeloid malignancies.<sup><xref rid="bibr7-1176935120972377" ref-type="bibr">7</xref>,<xref rid="bibr8-1176935120972377" ref-type="bibr">8</xref></sup> High throughput sequencing can be used as an alternative to polymerase chain reaction (PCR)-based clinical analysis of mutant allele burden,<sup><xref rid="bibr9-1176935120972377" ref-type="bibr">9</xref></sup> with the advantage that it has the potential to provide an accurate estimate of the mutant frequency and can detect clinically relevant mutations that are not targeted a priori. Moreover, mutational signatures that can be recovered from high throughput sequencing data have been associated with distinct clinical outcomes and are emerging as potential biomarkers for novel targeted therapies.<sup><xref rid="bibr10-1176935120972377" ref-type="bibr">10</xref></sup></p>
    <p>There are significant technical challenges that inhibit the application of next-generation sequencing in cancer treatment, including the lack of user-friendly tools and data analysis pipelines.<sup><xref rid="bibr11-1176935120972377" ref-type="bibr">11</xref></sup> The data derived from cancer sequencing is complex, making it difficult to extract information on relevant variants. Candidate variants flagged by the caller as having failed quality filters are routinely removed from analysis; however, they have the potential to highlight sources of technical artefacts. These variants may also contain false negatives that are of clinical or research interest. Command-line based, hard-filtering approaches such as VCFtools,<sup><xref rid="bibr2-1176935120972377" ref-type="bibr">2</xref></sup> GATK VariantFiltration,<sup><xref rid="bibr12-1176935120972377" ref-type="bibr">12</xref></sup> and SnpSift<sup><xref rid="bibr13-1176935120972377" ref-type="bibr">13</xref></sup> use variant attribute values combined with logical operators to further subset a VCF file. Such tools are complex to configure and lack a means to review the impact of analytical choices involved when subsetting the data. This significantly limits the scope and pace of exploratory analysis of VCF data.</p>
    <p>We developed vcfView as an interactive graphical tool to support filtering of putative somatic variants. vcfView displays the allele frequency spectrum as well as mutation patterns and signatures inferred from all putative mutations so that the user can assess the impact of different filtering choices on the variants discovered. All displays are updated dynamically as the user adjusts the filters that are applied to the data. Users can also display somatic mutations on a gene of interest, gaining insights about which mutations are lost from the gene as different filters are applied. To demonstrate its utility, we use vcfView to isolate putative tumour-in-normal (TiN) variants in acute myeloid leukaemia (AML) samples from The Cancer Genome Atlas (TCGA). These variants, which were removed from analysis in TCGA, were significant enrichment for known AML driver mutations.</p>
  </sec>
  <sec id="section5-1176935120972377">
    <title>Features</title>
    <p>vcfView enables users to analyse mutations that fall within a region of the mutation frequency spectrum and that pass or fail user-specified quality filters. Analyses available by default include mutation patterns, mutational signatures and the functional effects of the mutations on proteins of interest. The user can explore how these change in different regions of the frequency spectrum or when different filters or other user configurable thresholds are applied. The interface features a variant allele frequency (VAF) density plot within which a region of interest may be selected for further filtering or analysis. The results are displayed inset within the top corner of the density plot. An additional feature allows for a summary file created from a number of individual VCF files to be analysed to identify patterns that may exist across a collection of samples. High-resolution publication standard plots and a filtered copy of the original VCF file may be saved at any stage.</p>
    <sec id="section6-1176935120972377">
      <title>Density plot, thresholds, and filters</title>
      <p>The central window of the vcfView user interface is the VAF Density plot (<xref ref-type="fig" rid="fig1-1176935120972377">Figure 1</xref>) that displays the frequency spectrum of somatic mutations. To the right, a series of checkboxes present the researcher with the available quality filters, which are parsed directly from the input file, as well as user configurable thresholds for calling somatic mutations. These provide a means to threshold on the evidence for a somatic mutation at a site. Variants that pass all these filters are displayed in the VAF density plot. The colour in the plot indicates the median sequencing depth of variants in the VAF bin shown on the <italic>x</italic>-axis. All plot data are updated when the user modifies any filter or threshold settings. The density plot also includes interactive click and drag functionality, enabling the researcher to extract a region of interest from the allelic spectrum for further analysis.</p>
      <fig id="fig1-1176935120972377" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>vcfView user interface. Display shows the VAF Density plot with signatures inset plot active, filter panel to the right and inset function selection below.</p>
        </caption>
        <graphic xlink:href="10.1177_1176935120972377-fig1"/>
      </fig>
    </sec>
    <sec id="section7-1176935120972377">
      <title>Inset plots</title>
      <p>Variants that are included within the selected frequency range can be visualized in several alternative inset plots on the main VAF display (<xref ref-type="fig" rid="fig2-1176935120972377">Figure 2</xref>). The required inset function is specified using the radio button list below the density plot. The inset plot is triggered when one of these buttons is activated and redrawn when a region of the allelic spectrum is selected (either with the mouse or by updating the relevant numeric inputs on the user interface) or when filter/threshold settings are updated. vcfView is configured with four inset plots by default, displaying mutation signatures, mutation processes, functional impacts of variants on a selected protein, and candidate filters. The architecture is extensible allowing integration of third-party or custom algorithms to produce alternative inset plots. The signatures inset plot displays the estimated contribution of each of the Catalogue of Somatic Mutations in Cancer (COSMIC)<sup><xref rid="bibr14-1176935120972377" ref-type="bibr">14</xref></sup> reference signatures to the selected mutations. The mutation processes plot shows a bar plot of the fraction of the mutations in each of the 96 trinucleotide contexts.<sup><xref rid="bibr14-1176935120972377" ref-type="bibr">14</xref></sup> The protein function inset plot is a lollipop diagram indicating the functional impacts of mutations in the selected frequency range on the specified gene. The dropdown list from which this gene is chosen is updated dynamically so that only genes with a protein impacting variant in the selected frequency range are displayed. Finally, the candidate filters function shows the number of variants that have failed each variant caller filter within the selected range.</p>
      <fig id="fig2-1176935120972377" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>vcfView inset analysis function plots showing (A) protein analysis plot, (B) mutational signatures, (C) trinucleotide contexts, and (D) candidate filters plot.</p>
        </caption>
        <graphic xlink:href="10.1177_1176935120972377-fig2"/>
      </fig>
    </sec>
    <sec id="section8-1176935120972377">
      <title>Package vignette</title>
      <p>The package vignette demonstrates the functionality of vcfView using publicly available data from The Texas Cancer Research Biobank (TCRB). It is composed of three main sections. It first demonstrates exploratory analysis of a single VCF file from the data set. Mutational processes and signatures within a somatic allele frequency window are identified. Candidate variants within that region are subsetted according to various thresholds and filter settings, and the impact of selected variants on proteins of interest is visualized. This enables the evidence for the presence of potential driver variants to be assessed.</p>
      <p>The vignette also describes how to generate a summary of all VCF files within a data set to identify patterns that may exist across that cohort. A summary file is loaded into vcfView and analysed in the same way as an individual VCF file. It may be used, for example, to identify mutational signatures or processes across a data set from patients with the same cancer type or who have undergone the same therapy. It can help to determine if variants are impacting a putative driver gene across multiple patients. A subset of candidate variants that have failed specific filters may be re-examined in an attempt to recover information previously excluded from analysis. In the vignette, a summary file is created and used to check for the existence of putative tumour-in-normal variants within the TCRB data set that may have resulted in failure to call some cancer somatic variants.</p>
      <p>Finally, the vignette shows how to integrate other packages into vcfView to produce additional inset plots. It provides a simple wrapper example that integrates a third-party algorithm with vcfView’s extensible function set. This enables the researcher to use that library within the inset window of vcfView and take advantage of its preprocessing capabilities.</p>
    </sec>
  </sec>
  <sec id="section9-1176935120972377">
    <title>vcfView Architecture</title>
    <p>Interactive visualization is implemented in <italic>R</italic><sup><xref rid="bibr15-1176935120972377" ref-type="bibr">15</xref></sup> with Shiny.<sup><xref rid="bibr16-1176935120972377" ref-type="bibr">16</xref></sup> All data processing is performed within the <italic>R</italic> environment to facilitate platform independence. It leverages several Bioconductor packages<sup><xref rid="bibr17-1176935120972377" ref-type="bibr">17</xref><xref rid="bibr18-1176935120972377" ref-type="bibr"/><xref rid="bibr19-1176935120972377" ref-type="bibr"/><xref rid="bibr20-1176935120972377" ref-type="bibr"/>–<xref rid="bibr21-1176935120972377" ref-type="bibr">21</xref></sup> to functionally annotate VCF-formatted data and drive exploratory visualizations within a user-selectable allele frequency window.</p>
    <p>VCF-based record details together with amino acid and trinucleotide context annotation is maintained in two internal data structures for ease of manipulation and subsetting. An index into the original VCF object is used to save a subsetted version of the VCF as required. Functional annotation of protein impact (enumerated as frameshift, nonsense, nonsynonymous, or synonymous) provided by the UCSC transcript annotation library<sup><xref rid="bibr19-1176935120972377" ref-type="bibr">19</xref></sup> is displayed by the protein inset function using ggplot<sup><xref rid="bibr22-1176935120972377" ref-type="bibr">22</xref></sup> and labelled using ggrepel.<sup><xref rid="bibr23-1176935120972377" ref-type="bibr">23</xref></sup></p>
    <p>Single base substitution (SBS) trinucleotide sequence context annotation for inset function signatures and mutational processes is provided by the Bsgenome annotation library.<sup><xref rid="bibr18-1176935120972377" ref-type="bibr">18</xref></sup> In the signatures inset function, a summary of this annotation is used in conjunction with the lsqnonneg method (from pracma library)<sup><xref rid="bibr24-1176935120972377" ref-type="bibr">24</xref></sup> to create the optimal combination of COSMIC v3 SBS signatures required to reconstruct the variant subset. This returns a non-negative linear least-squares fit of the 65 COSMIC mutational signatures (version 3). Processing is similar to that used in the MutationalPatterns<sup><xref rid="bibr25-1176935120972377" ref-type="bibr">25</xref></sup> library but streamlined to reduce demands on system memory. All plots are rendered using the ggplot<sup><xref rid="bibr22-1176935120972377" ref-type="bibr">22</xref></sup> library.</p>
  </sec>
  <sec id="section10-1176935120972377">
    <title>Visualization of Putative Tumour in Normal Variants in Leukaemia Samples With vcfView</title>
    <p>To demonstrate the utility of vcfView, we used it to re-examine TCGA AML data to determine whether potentially relevant prognostic or diagnostic information could be recovered from candidate variants that have previously been excluded from analysis. Mutect2 filters potential false positives resulting from germline variants by scoring the confidence that a mutation is present in the tumour sample and absent from matched normal, typically a skin sample in the case of blood cancers. This could result in the failure to detect true somatic variants in the cancer if the same mutation is found in a subset of the cells in the skin sample or if the skin sample includes a proportion of cancer cells or cell-free DNA. Many cancer driver mutations have been found to be relatively common in normal skin cells.<sup><xref rid="bibr26-1176935120972377" ref-type="bibr">26</xref></sup> Moreover, 3% to 5% of all nucleated cells in the epidermis are myeloid derived.<sup><xref rid="bibr27-1176935120972377" ref-type="bibr">27</xref></sup> Therefore, it is possible that some of the driver mutations that are critical for gaining an insight into the cancer may also occur, albeit potentially at a lower level, in the skin sample. The use of skin as a normal sample for the identification of somatic mutations in leukaemia cells risks removing these variants from analysis. Mutect2 filters variants that are identified in a panel of normal samples to reduce the effects of recurrent sequencing artefacts and common genetic variation. This variant blacklist is usually derived from blood samples; however, a substantial proportion of blood samples may be affected by clonal haematopoiesis and contain somatic mutations that are relevant for blood cancers.<sup><xref rid="bibr28-1176935120972377" ref-type="bibr">28</xref></sup> Here, we used vcfView to re-examine data from TCGA LAML samples for evidence of somatic variant exclusion due to the presence in the matched normal sample or in the panel of normals. We refer to these variants as putative tumour-in-normal (pTiN).</p>
    <p>Exploratory analysis with vcfView highlighted a significant number of candidate variants that had been removed solely because they failed the allele in normal filter despite being present in extremely low amounts in the normal sample relative to the tumour. Further inspection with the protein inset function revealed a large number of these were in known AML drivers. We tested for enrichment of pTiN variants among known AML driver genes and isolated a significant number of pTiN AML driver variants previously excluded from analysis in TCGA LAML.</p>
  </sec>
  <sec sec-type="methods" id="section11-1176935120972377">
    <title>Methods</title>
    <p>We downloaded the protected mutation annotation format (MAF) file containing variants previously identified in the TCGA LAML data set of 149 AML patient samples from the NCI’s Genomic Data Commons (GDC, <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/files/66124158-7feb-4b8e-8fc4-393a5e641fea">https://portal.gdc.cancer.gov/files/66124158-7feb-4b8e-8fc4-393a5e641fea</ext-link>). We retrieved all protein-truncating variants that had failed the allele in normal and/or panel of normal Mutect2 filters for which the VAF was greater than 0.1 and at least 10 times the frequency of the variant in the normal samples. We further restricted to variants at loci with a read depth of at least 20 in both the tumour and normal samples and that were not found in dbSNP.</p>
    <p>We next obtained a list of canonical transcript lengths for all protein coding genes in the exome from Ensembl. Further annotation was added to each gene in this list identifying it as AML driver or non-AML driver (as indicated by IntOGen)<sup><xref rid="bibr29-1176935120972377" ref-type="bibr">29</xref></sup> and recording the number of pTiN variants contained per base of coding sequence. We performed Fisher’s exact test for enrichment of known AML drivers among genes containing pTiN variants. To account for coding sequence length, we also compared the number of pTiN variants per base between AML driver genes and non-AML drivers using the Wilcoxon rank sum test.</p>
  </sec>
  <sec sec-type="results" id="section12-1176935120972377">
    <title>Results</title>
    <p>A total of 3549 protein-truncating variants were flagged as occurring in the normal sample or panel of normals and were, therefore, not called as cancer somatic variants. Of these, 129 met all of the criteria we used for identifying pTiN variants (<xref rid="table1-1176935120972377" ref-type="table">Table 1</xref>: see Methods for details). Among these pTiN variants, 16 occurred in AML driver genes obtained from IntOGen<sup><xref rid="bibr29-1176935120972377" ref-type="bibr">29</xref></sup> (<xref ref-type="fig" rid="fig3-1176935120972377">Figure 3A</xref>). One additional variant, RUNX11, not listed as a driver in IntOGen, was reported to be relevant to AML<sup><xref rid="bibr30-1176935120972377" ref-type="bibr">30</xref></sup> and is included in <xref ref-type="fig" rid="fig3-1176935120972377">Figure 3A</xref>.</p>
    <table-wrap id="table1-1176935120972377" orientation="portrait" position="float">
      <label>Table 1.</label>
      <caption>
        <p>Genes and patients affected by pTiN variants relevant to AML in TCGA AML.</p>
      </caption>
      <alternatives>
        <graphic xlink:href="10.1177_1176935120972377-table1"/>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">pTiN Gene</th>
              <th align="left" rowspan="1" colspan="1">Patient</th>
              <th align="left" rowspan="1" colspan="1">Reason for variant removal</th>
              <th align="left" rowspan="1" colspan="1">Clinical relevance</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">ASXL1</td>
              <td rowspan="1" colspan="1">TCGA-AB-2917</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Prats-Martin et al<sup><xref rid="bibr31-1176935120972377" ref-type="bibr">31</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">EZH2</td>
              <td rowspan="1" colspan="1">TCGA-AB-2817</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Mechaal et al<sup><xref rid="bibr32-1176935120972377" ref-type="bibr">32</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">FAT4</td>
              <td rowspan="1" colspan="1">TCGA-AB-2863</td>
              <td rowspan="1" colspan="1">Panel of normal</td>
              <td rowspan="1" colspan="1">Garg et al<sup><xref rid="bibr33-1176935120972377" ref-type="bibr">33</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">KMT2C</td>
              <td rowspan="1" colspan="1">TCGA-AB-2940</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Rampias et al<sup><xref rid="bibr34-1176935120972377" ref-type="bibr">34</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">NPM1</td>
              <td rowspan="1" colspan="1">TCGA-AB-2900, TCGA-AB-2924</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Lachowiez et al<sup><xref rid="bibr35-1176935120972377" ref-type="bibr">35</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PHF6</td>
              <td rowspan="1" colspan="1">TCGA-AB-2912</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Przychodzen et al<sup><xref rid="bibr36-1176935120972377" ref-type="bibr">36</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">RUNX1</td>
              <td rowspan="1" colspan="1">TCGA-AB-2805, TCGA-AB-2890, TCGA-AB-2927</td>
              <td rowspan="1" colspan="1">Allele in normal and panel of normal</td>
              <td rowspan="1" colspan="1">Jalili et al<sup><xref rid="bibr37-1176935120972377" ref-type="bibr">37</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">TET2</td>
              <td rowspan="1" colspan="1">TCGA-AB-2876, TCGA-AB-2882</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Wang et al<sup><xref rid="bibr38-1176935120972377" ref-type="bibr">38</xref></sup></td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">TP53</td>
              <td rowspan="1" colspan="1">TCGA-AB-2820, TCGA-AB-2860, TCGA-AB-2878</td>
              <td rowspan="1" colspan="1">Allele in normal</td>
              <td rowspan="1" colspan="1">Barbosa et al<sup><xref rid="bibr39-1176935120972377" ref-type="bibr">39</xref></sup></td>
            </tr>
          </tbody>
        </table>
      </alternatives>
    </table-wrap>
    <fig id="fig3-1176935120972377" orientation="portrait" position="float">
      <label>Figure: 3.</label>
      <caption>
        <p>(A) Alternative allele frequency plot of tumour (blue) and matched normal (red) TCGA LAML pTiN variants affecting AML-relevant genes. Error bars show 95% confidence intervals for the alternative allele frequency (estimated from reference and alternative read counts). (B) vcfView protein plot for NPM1 derived from a VCF summary of the TCGA LAML data set.</p>
      </caption>
      <graphic xlink:href="10.1177_1176935120972377-fig3"/>
    </fig>
    <p>AML driver genes were significantly enriched among the set of genes affected by these 129 pTiN variants (<italic>P</italic> = 3 × 10<sup>−11</sup>, Fisher’s Exact Test). This difference was also highly statistically significant when we compared the number of pTiN variants per base pair between AML driver genes and other genes to account for differences in length between genes in the two groups (<italic>P</italic> = 1 × 10<sup>−53</sup>, Wilcoxon rank-sum test). In all, variants in 9 genes of prognostic or diagnostic value were identified in 15 patients (<xref rid="table1-1176935120972377" ref-type="table">Table 1</xref>). Thus, 10% of TCGA LAML patients had potential clinically actionable variants overlooked due to pTiN. For example, two patients had pTiN variants in NPM1 (<xref ref-type="fig" rid="fig3-1176935120972377">Figure 3B</xref>). This would be of potential prognostic value for these patients, as mutations in NPM1, which occur in approximately 30% of patients with AML, are associated with favourable response to standard intensive chemotherapy.<sup><xref rid="bibr35-1176935120972377" ref-type="bibr">35</xref></sup></p>
  </sec>
  <sec id="section13-1176935120972377">
    <title>Limitations</title>
    <p>This tool is intended for use with matched cancer/normal VCF files only (not for germline VCFs). Although it has been used with VCFs generated by other callers, it is recommended for use with Mutect2 VCFs. It uses the Mutect2-specific ‘TLOD’ subfield to select within records that contain multiple possible alternative alleles. As other callers do not provide this value in their VCFs non-Mutect2 records containing multiple possible alternative alleles are currently discarded by vcfView. We intend to add an option in a future release allowing the user to specify the field and condition used to calculate the index required to select among multiple possible alternative alleles when using vcfView with VCFs generated by callers other than Mutect2. vcfView has been tested with tumour exome data from MuTect2 GATK3 and Mutect2 GATK4 VCF files.<sup><xref rid="bibr4-1176935120972377" ref-type="bibr">4</xref></sup> We cannot guarantee it will work with all future versions of GATK without requiring modification. Mitochondrial DNA variants are currently excluded. We intend to add an option for their inclusion in a future release.</p>
  </sec>
</body>
<back>
  <ack>
    <p>The author would like to acknowledge the TCGA data as it relates to data analyzed in the study.</p>
  </ack>
  <fn-group>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding:</bold>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This publication has emanated from research conducted with the financial support of Science Foundation Ireland (grant no. 16/IA/4612).</p>
    </fn>
    <fn fn-type="COI-statement">
      <p><bold>Declaration of conflicting interests:</bold>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
    </fn>
    <fn fn-type="con">
      <p><bold>Author Contributions:</bold> BOS developed the concept and wrote the code. CS supervised the research and suggested additional features and analyses. The authors co-wrote the paper.</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="bibr1-1176935120972377">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Comparing the performance of selected variant callers using synthetic data and genome segmentation</article-title>. <source>BMC Bioinformatics</source>. <year>2018</year>;<volume>19</volume>:<fpage>429</fpage>.<pub-id pub-id-type="pmid">30453880</pub-id></mixed-citation>
    </ref>
    <ref id="bibr2-1176935120972377">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danecek</surname><given-names>P</given-names></name><name><surname>Auton</surname><given-names>A</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal><article-title>The variant call format and VCFtools</article-title>. <source>Bioinformatics (Oxford, England)</source>. <year>2011</year>;<volume>27</volume>:<fpage>2156</fpage>-<lpage>2158</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr3-1176935120972377">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartha</surname><given-names>A</given-names></name><name><surname>Gyorffy</surname><given-names>B.</given-names></name></person-group><article-title>Comprehensive outline of whole exome sequencing data analysis tools available in clinical oncology</article-title>. <source>Cancers</source>. <year>2019</year>;<volume>11</volume>: <year>1725</year>.</mixed-citation>
    </ref>
    <ref id="bibr4-1176935120972377">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name></person-group>, <etal>et al</etal><article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>. <source>Nat Biotechnol</source>. <year>2013</year>;<volume>31</volume>:<fpage>213</fpage>-<lpage>219</lpage>.<pub-id pub-id-type="pmid">23396013</pub-id></mixed-citation>
    </ref>
    <ref id="bibr5-1176935120972377">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MJ</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Barnes</surname><given-names>CP</given-names></name><name><surname>Graham</surname><given-names>TA</given-names></name><name><surname>Sottoriva</surname><given-names>A.</given-names></name></person-group><article-title>Identification of neutral tumor evolution across cancer types</article-title>. <source>Nature Genetics</source>. <year>2016</year>;<volume>48</volume>:<fpage>238</fpage>-<lpage>244</lpage>.<pub-id pub-id-type="pmid">26780609</pub-id></mixed-citation>
    </ref>
    <ref id="bibr6-1176935120972377">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MJ</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Heide</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal><article-title>Quantification of subclonal selection in cancer from bulk sequencing data</article-title>. <source>Nat Genet</source>. <year>2018</year>;<volume>50</volume>:<fpage>895</fpage>-<lpage>903</lpage>.<pub-id pub-id-type="pmid">29808029</pub-id></mixed-citation>
    </ref>
    <ref id="bibr7-1176935120972377">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagheropur</surname><given-names>S</given-names></name><name><surname>Ehsanpour</surname><given-names>A</given-names></name><name><surname>Birgani</surname><given-names>MT</given-names></name><name><surname>Saki</surname><given-names>N.</given-names></name></person-group><article-title>JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms</article-title>. <source>Memo</source>. <year>2018</year>;<volume>11</volume>:<fpage>152</fpage>-<lpage>157</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr8-1176935120972377">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratcorona</surname><given-names>M</given-names></name><name><surname>Brunet</surname><given-names>S</given-names></name><name><surname>Nomdedéu</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy</article-title>. <source>Blood</source>. <year>2013</year>;<volume>121</volume>:<fpage>2734</fpage>-<lpage>2738</lpage>.<pub-id pub-id-type="pmid">23377436</pub-id></mixed-citation>
    </ref>
    <ref id="bibr9-1176935120972377">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallman</surname><given-names>DA</given-names></name><name><surname>Padron</surname><given-names>E.</given-names></name></person-group><article-title>Integrating mutation variant allele frequency into clinical practice in myeloid malignancies</article-title>. <source>Hematol Oncol Stem Cell Ther</source>. <year>2016</year>;<volume>9</volume>:<fpage>89</fpage>-<lpage>95</lpage>.<pub-id pub-id-type="pmid">27187622</pub-id></mixed-citation>
    </ref>
    <ref id="bibr10-1176935120972377">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maura</surname><given-names>F</given-names></name><name><surname>Degasperi</surname><given-names>A</given-names></name><name><surname>Nadeu</surname><given-names>F</given-names></name></person-group>, <etal>et al</etal><article-title>A practical guide for mutational signature analysis in hematological malignancies</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>:<year>2969</year>.</mixed-citation>
    </ref>
    <ref id="bibr11-1176935120972377">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messner</surname><given-names>DA</given-names></name><name><surname>Al Naber</surname><given-names>J</given-names></name><name><surname>Koay</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal><article-title>Barriers to clinical adoption of next generation sequencing: perspectives of a policy Delphi panel</article-title>. <source>Appl Transl Genom</source>. <year>2016</year>;<volume>10</volume>:<fpage>19</fpage>-<lpage>24</lpage>.<pub-id pub-id-type="pmid">27668172</pub-id></mixed-citation>
    </ref>
    <ref id="bibr12-1176935120972377">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal><article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>. <source>Genome Res</source>. <year>2010</year>;<volume>20</volume>:<fpage>1297</fpage>-<lpage>1303</lpage>.<pub-id pub-id-type="pmid">20644199</pub-id></mixed-citation>
    </ref>
    <ref id="bibr13-1176935120972377">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cingolani</surname><given-names>P</given-names></name><name><surname>Patel</surname><given-names>VM</given-names></name><name><surname>Coon</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift</article-title>. <source>Front Genet</source>. <year>2012</year>;<volume>3</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">22435069</pub-id></mixed-citation>
    </ref>
    <ref id="bibr14-1176935120972377">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name></person-group>, <etal>et al</etal><article-title>Signatures of mutational processes in human cancer</article-title>. <source>Nature</source>. <year>2013</year>;<volume>500</volume>:<fpage>415</fpage>-<lpage>421</lpage>.<pub-id pub-id-type="pmid">23945592</pub-id></mixed-citation>
    </ref>
    <ref id="bibr15-1176935120972377">
      <label>15.</label>
      <mixed-citation publication-type="book"><collab>R Core Team</collab>. <source>R: A Language and Environment for Statistical Computing</source>. <publisher-loc>Vienna</publisher-loc>: <publisher-name>R Core Team</publisher-name>; <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="bibr16-1176935120972377">
      <label>16.</label>
      <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Allaire</surname><given-names>JJ</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>McPherson</surname><given-names>J</given-names></name></person-group><source>Shiny: Web Application Framework for R 2019</source>. <ext-link ext-link-type="uri" xlink:href="https://rdrr.io/cran/shiny/">https://rdrr.io/cran/shiny/</ext-link>.</mixed-citation>
    </ref>
    <ref id="bibr17-1176935120972377">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obenchain</surname><given-names>V</given-names></name><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Carey</surname><given-names>V</given-names></name><name><surname>Gogarten</surname><given-names>S</given-names></name><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Morgan</surname><given-names>M.</given-names></name></person-group><article-title>VariantAnnotation: a bioconductor package for exploration and annotation of genetic variants</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>:<fpage>2076</fpage>-<lpage>2078</lpage>.<pub-id pub-id-type="pmid">24681907</pub-id></mixed-citation>
    </ref>
    <ref id="bibr18-1176935120972377">
      <label>18.</label>
      <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>eam</surname><given-names>TBD</given-names></name></person-group><source>Bsgenome.hsapiens.ucsc.hg38: Full Genome Sequences for Homo Sapiens (UCSC Version Hg38) 2015</source>. <ext-link ext-link-type="uri" xlink:href="https://bioconductor.riken.jp/packages/3.8/data/annotation/html/BSgenome.Hsapiens.UCSC.hg38.html">https://bioconductor.riken.jp/packages/3.8/data/annotation/html/BSgenome.Hsapiens.UCSC.hg38.html</ext-link>.</mixed-citation>
    </ref>
    <ref id="bibr19-1176935120972377">
      <label>19.</label>
      <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>Team</surname><given-names>BC</given-names></name><name><surname>Maintainer</surname><given-names>BP</given-names></name></person-group><source>Txdb.hsapiens.ucsc.hg38.knowngene: Annotation Package for Txdb Object(s) 2019</source>. <ext-link ext-link-type="uri" xlink:href="http://bioconductor.org/packages/release/data/annotation/html/TxDb.Hsapiens.UCSC.hg38.knownGene.html">http://bioconductor.org/packages/release/data/annotation/html/TxDb.Hsapiens.UCSC.hg38.knownGene.html</ext-link>.</mixed-citation>
    </ref>
    <ref id="bibr20-1176935120972377">
      <label>20.</label>
      <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>M</given-names></name></person-group><source>Org.hs.eg.db: Genome Wide Annotation for Human 2019</source>. <ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/data/annotation/html/org.Hs.eg.db.html">https://bioconductor.org/packages/release/data/annotation/html/org.Hs.eg.db.html</ext-link>.</mixed-citation>
    </ref>
    <ref id="bibr21-1176935120972377">
      <label>21.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gentleman</surname><given-names>R</given-names></name></person-group><source>Annotate: Annotation for Microarrays 2019</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>.</mixed-citation>
    </ref>
    <ref id="bibr22-1176935120972377">
      <label>22.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H.</given-names></name></person-group><source>Ggplot2: Elegant Graphics for Data Analysis</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>2016</year>.</mixed-citation>
    </ref>
    <ref id="bibr23-1176935120972377">
      <label>23.</label>
      <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>Slowikowski</surname><given-names>K</given-names></name></person-group><source>Ggrepel: Automatically Position Non-overlapping Text Labels with ‘Ggplot2’ 2019</source>. <ext-link ext-link-type="uri" xlink:href="https://rdrr.io/cran/ggrepel/">https://rdrr.io/cran/ggrepel/</ext-link>.</mixed-citation>
    </ref>
    <ref id="bibr24-1176935120972377">
      <label>24.</label>
      <mixed-citation publication-type="web"><person-group person-group-type="author"><name><surname>Borchers</surname><given-names>HW</given-names></name></person-group><source>Pracma: Practical Numerical Math Functions 2019</source>. <ext-link ext-link-type="uri" xlink:href="https://rdrr.io/cran/pracma/">https://rdrr.io/cran/pracma/</ext-link>.</mixed-citation>
    </ref>
    <ref id="bibr25-1176935120972377">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blokzijl</surname><given-names>F</given-names></name><name><surname>Janssen</surname><given-names>R</given-names></name><name><surname>van Boxtel</surname><given-names>R</given-names></name><name><surname>Cuppen</surname><given-names>E.</given-names></name></person-group><article-title>MutationalPatterns: comprehensive genome-wide analysis of mutational processes</article-title>. <source>Genome Medicine</source>. <year>2018</year>;<volume>10</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">29695279</pub-id></mixed-citation>
    </ref>
    <ref id="bibr26-1176935120972377">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Roshan</surname><given-names>A</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin</article-title>. <source>Science (New York, N.Y.)</source>. <year>2015</year>;<volume>348</volume>:<fpage>880</fpage>-<lpage>886</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr27-1176935120972377">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deckers</surname><given-names>J</given-names></name><name><surname>Hammad</surname><given-names>H</given-names></name><name><surname>Hoste</surname><given-names>E.</given-names></name></person-group><article-title>Langerhans cells: sensing the environment in health and disease</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<fpage>93</fpage>-<lpage>93</lpage>.<pub-id pub-id-type="pmid">29449841</pub-id></mixed-citation>
    </ref>
    <ref id="bibr28-1176935120972377">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlush</surname><given-names>LI.</given-names></name></person-group><article-title>Age-related clonal hematopoiesis</article-title>. <source>Blood</source>. <year>2018</year>;<volume>131</volume>:<fpage>496</fpage>-<lpage>504</lpage>.<pub-id pub-id-type="pmid">29141946</pub-id></mixed-citation>
    </ref>
    <ref id="bibr29-1176935120972377">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Perez-Llamas</surname><given-names>C</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>IntOGen-mutations identifies cancer drivers across tumor types</article-title>. <source>Nat Methods</source>. <year>2013</year>;<volume>10</volume>:<fpage>1081</fpage>-<lpage>1082</lpage>.<pub-id pub-id-type="pmid">24037244</pub-id></mixed-citation>
    </ref>
    <ref id="bibr30-1176935120972377">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haferlach</surname><given-names>T</given-names></name><name><surname>Meggendorfer</surname><given-names>M.</given-names></name></person-group><article-title>More than a fusion gene: the RUNX1-RUNX1T1 AML</article-title>. <source>Blood. March</source>. <year>2019</year>;<volume>133</volume>:<fpage>1006</fpage>-<lpage>1007</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr31-1176935120972377">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prats-Martín</surname><given-names>C</given-names></name><name><surname>Burillo-Sanz</surname><given-names>S</given-names></name><name><surname>Morales-Camacho</surname><given-names>RM</given-names></name></person-group>, <etal>et al</etal><article-title>ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype</article-title>. <source>Cancer Med</source>. <year>2020</year>;<volume>9</volume>:<fpage>3637</fpage>-<lpage>3646</lpage>.<pub-id pub-id-type="pmid">32216059</pub-id></mixed-citation>
    </ref>
    <ref id="bibr32-1176935120972377">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechaal</surname><given-names>A</given-names></name><name><surname>Menif</surname><given-names>S</given-names></name><name><surname>Abbes</surname><given-names>S</given-names></name><name><surname>Safra</surname><given-names>I.</given-names></name></person-group><article-title>EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients</article-title>. <source>Adv Med Sci</source>. <year>2019</year>;<volume>64</volume>:<fpage>395</fpage>-<lpage>401</lpage>.<pub-id pub-id-type="pmid">31331874</pub-id></mixed-citation>
    </ref>
    <ref id="bibr33-1176935120972377">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Kanojia</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse</article-title>. <source>Blood</source>. <year>2015</year>;<volume>126</volume>:<fpage>2491</fpage>-<lpage>2501</lpage>.<pub-id pub-id-type="pmid">26438511</pub-id></mixed-citation>
    </ref>
    <ref id="bibr34-1176935120972377">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampias</surname><given-names>T</given-names></name><name><surname>Karagiannis</surname><given-names>D</given-names></name><name><surname>Avgeris</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer</article-title>. <source>EMBO Rep</source>. <year>2019</year>;<volume>20</volume>:<fpage>e46821</fpage>.<pub-id pub-id-type="pmid">30665945</pub-id></mixed-citation>
    </ref>
    <ref id="bibr35-1176935120972377">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachowiez</surname><given-names>CA</given-names></name><name><surname>Loghavi</surname><given-names>S</given-names></name><name><surname>Kadia</surname><given-names>TM</given-names></name></person-group>, <etal>et al</etal><article-title>Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens</article-title>. <source>Blood Advances</source>. <year>2020</year>;<volume>4</volume>:<fpage>1311</fpage>-<lpage>1320</lpage>.<pub-id pub-id-type="pmid">32251497</pub-id></mixed-citation>
    </ref>
    <ref id="bibr36-1176935120972377">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przychodzen</surname><given-names>BP</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>You</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>PHF6 somatic mutations and their functional role in the pathophysiology of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)</article-title>. <source>Blood</source>. <year>2016</year>;<volume>128</volume>:<fpage>2736</fpage>-<lpage>2736</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr37-1176935120972377">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jalili</surname><given-names>M</given-names></name><name><surname>Yaghmaie</surname><given-names>M</given-names></name><name><surname>Ahmadvand</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal><article-title>Prognostic value of RUNX1 mutations in AML: a meta-analysis</article-title>. <source>APJCP</source>. <year>2018</year>;<volume>19</volume>:<fpage>325</fpage>-<lpage>329</lpage>.<pub-id pub-id-type="pmid">29479958</pub-id></mixed-citation>
    </ref>
    <ref id="bibr38-1176935120972377">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name></person-group><article-title>The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis</article-title>. <source>BMC Cancer</source>. <year>2019</year>;<volume>19</volume>:<fpage>389</fpage>.<pub-id pub-id-type="pmid">31023266</pub-id></mixed-citation>
    </ref>
    <ref id="bibr39-1176935120972377">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbosa</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Deshpande</surname><given-names>AJ.</given-names></name></person-group><article-title>The role of TP53 in acute myeloid leukemia: challenges and opportunities</article-title>. <source>Genes Chromosomes Cancer</source>. <year>2019</year>;<volume>58</volume>:<fpage>875</fpage>-<lpage>888</lpage>.<pub-id pub-id-type="pmid">31393631</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
